Abstract
Patients with hematologic malignancies are at higher risk for invasive fungal infections (IFI) mainly patients with acute myeloid leukemia. Antifungal prophylaxis can help to decrease the incidence of these infections and their related complications. Prospective study compared to historical control data included 136 newly diagnosed Acute Myeloid Leukemia patients treated at the National Cancer Institute, Cairo University from 2011 to 2014. The prospective group received primary Voriconazole compared to retrospective control regarding the infectious complications and incidence of fungal infection. Results showed that one hundred thirty-six (136) newly diagnosed pediatric AML patients were included in the study, 61 patients didn't receive antifungal prophylaxis (Non- prophylactic arm) while 75 patients received voriconazole prophylaxis (prophylactic arm). The median age among both groups was 5.5 years old. Thirty-one (50%) of the 61 patients in (non - prophylactic arm) and five (6.6%) of the 75 patients enrolled in group B (prophylactic arm) developed an invasive fungal infection. The most commonly affected sites were pulmonary (34/ 36) while fungal sinus infection was reported in 2 patients. Most patients develop an invasive fungal infection during the induction treatment phase. Primary prophylaxis with voriconazole had a highly statistically significant impact on the reduction of incidence of invasive fungal infection between 2 groups (p value.001). Fungal attributable mortality was reported in 8 patients (13%) in the historical group (no antifungal prophylaxis) in comparison to 2 patients (2.6%) in group patients received voriconazole antifungal prophylaxis. Three Overall and Event-free survival were comparable between both groups. In conclusion, Prophylactic Voriconazole significantly decreased the incidence of fungal infections but it had no impact on diseases or overall survival outcome. Bacterial sepsis and disease-related mortality was the main cause of deaths among our group patients.
Highlights
Invasive fungal infections (IFIs) are a serious threat to pediatric patients with hematological malignancies undergoing chemotherapy or hematopoietic stem cell transplantation
One hundred thirty-six (136) newly diagnosed pediatric acute myeloid leukemia (AML) patients were included in the study, 61 patients didn’t receive antifungal prophylaxis while 75 patients received voriconazole prophylaxis
(one patient proved to be invasive aspergillosis by histopathology), we did not see a significant increase in cases of zygomycosis keeping in mind a small number of patients and lacking diagnostic tools for biopsy and histopathological identification
Summary
Invasive fungal infections (IFIs) are a serious threat to pediatric patients with hematological malignancies undergoing chemotherapy or hematopoietic stem cell transplantation. The incidence of IFIs is higher in acute myeloid leukemia (AML) [1]. Nonspecific clinical manifestations make prompt IFI diagnosis challenging, and conventional diagnostic tests for IFI detection in cancer children are either insensitive or need further validation [4]. For these reasons, prevention of their development constitutes an optimal way to improve outcomes of IFIs in pediatric patients. The majority of AML patients usually experience IA after the first cycle induction of chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.